Autologous Bone Marrow-derived Mononuclear Cells for Acute Spinal Cord Injury
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of intrathecal
transplantation of autologous bone marrow-derived mononuclear cells for the treatment of
traumatic acute spinal cord injury. Spinal cord injury can be divided into three phases,
which are acute (within 2 weeks), sub-acute (2 weeks to 6 months), and chronic (over 6
months). Early treatment is the key to improve the prognosis, however, the majority of clinic
trails nowadays are focusing on sub-acute or chronic phase because it takes 4-6 weeks to
expand the autologous stem cells. In this study, the investigators will treat patients with
acute spinal cord injury with autologous bone marrow-derived mononuclear cells and compare
with the control group.